FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380684603> ?p ?o ?g. }

• W4380684603 abstract "Abstract Background Data and experience with delafloxacin use in osteomyelitis (OM) and other deep-seated infections are limited, yet the burden of OM on healthcare systems is significant. We hereby describe the first case, to our knowledge, of delafloxacin use in OM. Case description A 94-year-old male with a history of prostate cancer, hypertension and heart failure was admitted to hospital in June 2022 with grade 4 bilateral heel ulcers. Empirical IV co-amoxiclav was started and then escalated to IV piperacillin/tazobactam. MRI scans confirmed the diagnosis of OM, and tissue and bone samples grew MDR Pseudomonas aeruginosa (piperacillin/tazobactam-resistant and ciprofloxacin intermediate), an additional challenge. Due to this result and poor clinical response, IV meropenem was prescribed. Off-label use of delafloxacin was discussed within the multidisciplinary team (MDT) to switch to oral administration, decrease length of hospital stay and account for the patient’s age and co-morbidities. Minimum inhibitory concentration of the MDR P. aeruginosa using EUCAST guidelines demonstrated delafloxacin susceptibility (0.125 mg/L). Delafloxacin also has good bioavailability and does not require therapeutic drug monitoring. The patient was started on 450 mg delafloxacin twice daily with monitoring of clinical response. After 10 days of initial in-hospital clinical monitoring, the patient was discharged home with 450 mg twice daily delafloxacin to complete 28 days of therapy. Follow-up imaging was not planned given his age and co-morbidities. District nurses reported improvement in his heel ulcers. On follow-up telephone consultation with the treating consultant in November 2022, the patient reported feeling well and noted improvement in his ulcers. Readmission and adverse events have not been reported to date and the ulcers continue to improve. Conclusions This case presents the first successful use of delafloxacin in osteomyelitis, with good tolerability and clinical response against MDR P. aeruginosa. Delafloxacin enabled our patient to be discharged 3 weeks earlier than planned which would otherwise not have been possible, improving his quality of life and reducing risk of hospital-acquired infections with associated costs. Delafloxacin also enables early IV to oral switch in support of the antimicrobial stewardship agenda." @default.
• W4380684603 created "2023-06-15" @default.
• W4380684603 creator A5070714854 @default.
• W4380684603 creator A5092171196 @default.
• W4380684603 creator A5029934585 @default.
• W4380684603 date "2023-06-01" @default.
• W4380684603 modified "2023-09-25" @default.
• W4380684603 title "P41 Use of delafloxacin in osteomyelitis: a case report" @default.
• W4380684603 doi "https://doi.org/10.1093/jacamr/dlad066.045" @default.
• W4380684603 hasPublicationYear "2023" @default.
• W4380684603 type Work @default.
• W4380684603 citedByCount "0" @default.
• W4380684603 crossrefType "journal-article" @default.
• W4380684603 hasAuthorship W4380684603A5029934585 @default.
• W4380684603 hasAuthorship W4380684603A5070714854 @default.
• W4380684603 hasAuthorship W4380684603A5092171196 @default.
• W4380684603 hasBestOaLocation W43806846031 @default.
• W4380684603 hasConcept C105702510 @default.
• W4380684603 hasConcept C141071460 @default.
• W4380684603 hasConcept C2777248721 @default.
• W4380684603 hasConcept C2777637488 @default.
• W4380684603 hasConcept C2778193466 @default.
• W4380684603 hasConcept C2778512257 @default.
• W4380684603 hasConcept C2779375183 @default.
• W4380684603 hasConcept C2780551157 @default.
• W4380684603 hasConcept C501593827 @default.
• W4380684603 hasConcept C523546767 @default.
• W4380684603 hasConcept C54355233 @default.
• W4380684603 hasConcept C71924100 @default.
• W4380684603 hasConcept C86803240 @default.
• W4380684603 hasConcept C89423630 @default.
• W4380684603 hasConcept C94665300 @default.
• W4380684603 hasConceptScore W4380684603C105702510 @default.
• W4380684603 hasConceptScore W4380684603C141071460 @default.
• W4380684603 hasConceptScore W4380684603C2777248721 @default.
• W4380684603 hasConceptScore W4380684603C2777637488 @default.
• W4380684603 hasConceptScore W4380684603C2778193466 @default.
• W4380684603 hasConceptScore W4380684603C2778512257 @default.
• W4380684603 hasConceptScore W4380684603C2779375183 @default.
• W4380684603 hasConceptScore W4380684603C2780551157 @default.
• W4380684603 hasConceptScore W4380684603C501593827 @default.
• W4380684603 hasConceptScore W4380684603C523546767 @default.
• W4380684603 hasConceptScore W4380684603C54355233 @default.
• W4380684603 hasConceptScore W4380684603C71924100 @default.
• W4380684603 hasConceptScore W4380684603C86803240 @default.
• W4380684603 hasConceptScore W4380684603C89423630 @default.
• W4380684603 hasConceptScore W4380684603C94665300 @default.
• W4380684603 hasIssue "Supplement_2" @default.
• W4380684603 hasLocation W43806846031 @default.
• W4380684603 hasOpenAccess W4380684603 @default.
• W4380684603 hasPrimaryLocation W43806846031 @default.
• W4380684603 hasRelatedWork W1970444606 @default.
• W4380684603 hasRelatedWork W1992380210 @default.
• W4380684603 hasRelatedWork W1995665133 @default.
• W4380684603 hasRelatedWork W2018407600 @default.
• W4380684603 hasRelatedWork W2029607217 @default.
• W4380684603 hasRelatedWork W2116817824 @default.
• W4380684603 hasRelatedWork W2525674296 @default.
• W4380684603 hasRelatedWork W3138687476 @default.
• W4380684603 hasRelatedWork W3182620678 @default.
• W4380684603 hasRelatedWork W2188621193 @default.
• W4380684603 hasVolume "5" @default.
• W4380684603 isParatext "false" @default.
• W4380684603 isRetracted "false" @default.
• W4380684603 workType "article" @default.